NCT07784725ClinicalTrials.gov
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity Without Type 2 Diabetes Mellitus (SELENE 1)
باختصار
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
المرحلة 3مطلوب 2,500 مشارك220 موقعاً16 دولة
الفئات
مسجَّلة في سجل واحد
- ClinicalTrials.govNCT07784725فتح هذا السجل في ClinicalTrials.govتمت المزامنة قبل أسبوعين
يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.
تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.
هل أنت مهتم بهذه الدراسة؟
تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Not stated: Registered after enrolment began (about 6 days after the recorded start)First posted 2026-08-25; recorded start 2026-08-19
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 212 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study, international in scope: 2,500 participants (target), run at 220 sites, across 16 countries.
How this score is built
- Enrolment34/40
2,500 participants (target)
- Site count25/25
212 sites
- Country count15/15
16 countries
- Planned duration8/10
Planned over about 34 months
- Sponsor scale10/10
AstraZeneca has led 1,017 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
ملخص
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
الحالات
- Obesity or Overweight
الأهلية
| الجنس | الجميع |
|---|---|
| الأعمار | 18 Years – لا حد أقصى |
| المتطوعون الأصحّاء | لا |
الأهلية كما كُتبت في السجل
الأهلية في عبارات بسيطة
لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.
تصميم الدراسة
| نوع الدراسة | تدخّلية |
|---|---|
| المرحلة | المرحلة 3 |
| التخصيص | معشّاة |
| نموذج التدخّل | PARALLEL |
| الغرض الأساسي | TREATMENT |
| التعمية | QUADRUPLE (4) |
| التجنيد | مطلوب 2,500 مشارك |
الجهة الراعية والمتعاونون
- AstraZeneca الجهة الراعية
الأذرع والتدخلات
- AZD6234 Dose 1EXPERIMENTAL
AZD6234 Dose 1
- AZD6234 Dose 2EXPERIMENTAL
AZD6234 Dose 2
- PlaceboPLACEBO_COMPARATOR
Matching placebo
التدخلات
- دواء Lenbelintide
IMP injected subcutaneously, once a week. Unit dose strength as per CSP.
- دواء Placebo
Placebo matching IMP dose injected subcutaneously, once a week.
مقاييس النتائج
مقياس النتيجة الأولي
Percent change in body weight from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 as compared to placebo in percent body weight change
الإطار الزمني 68 weeks
مقياس النتيجة الثانوي
Absolute change in weight (kg) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 as compared to placebo on absolute change in weight
الإطار الزمني 68 weeks
مقياس النتيجة الثانوي
Achievement of at least 5 % body weight loss from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 5%
الإطار الزمني 68 weeks
مقياس النتيجة الثانوي
Achievement of at least 10% body weight loss from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 10%
الإطار الزمني 68 weeks
مقياس النتيجة الثانوي
Change in waist circumference (cm) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 as compared to placebo on waist circumference change
الإطار الزمني 68 weeks
مقياس النتيجة الثانوي
Percent change in triglycerides from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 as compared to placebo on triglycerides percent change
الإطار الزمني 68 weeks
مقياس النتيجة الثانوي
Change in systolic blood pressure (mmHg) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 as compared to placebo on systolic blood pressure change
الإطار الزمني 68 weeks
مقياس النتيجة الثانوي
Percent change in fat mass from baseline at 68 weeks of treatment measured by DXA in the DXA Sub-Study subset
Body Composition Sub-study: To evaluate the effect of AZD6234 as compared to placebo on body composition change in the DXA subset of participants
الإطار الزمني 68 weeks
التواريخ
| تاريخ البدء | 19 أغسطس 2026 (فعلي) |
|---|---|
| الإتمام الأولي | 11 أغسطس 2028 (تقديري) |
| الإتمام | 21 مايو 2029 (تقديري) |
| أول نشر | 25 أغسطس 2026 (فعلي) |
| آخر تحديث | 30 أكتوبر 2026 |
| النتائج منشورة | غير مذكور في سجل السجل |
| آخر تأكيد للحالة | أكتوبر 2026 |
فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.
المواقع
76 موقعاً قيد التجنيد
Argentina
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Research Site | Buenos Aires | قيد التجنيد | |
| Research Site | Buenos Aires | قيد التجنيد | |
| Research Site | Ciudad de Buenos Aires | قيد التجنيد | |
| Research Site | Mendoza | قيد التجنيد | |
| Research Site | Ramos Mejía | لم يبدأ التجنيد بعد | |
| Research Site | Rosario | قيد التجنيد | |
| Research Site | San Nicolás | لم يبدأ التجنيد بعد |
Australia
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Research Site | Botany | قيد التجنيد | |
| Research Site | Camberwell | قيد التجنيد | |
| Research Site | Charlestown | قيد التجنيد | |
| Research Site | St Albans | قيد التجنيد | |
| Research Site | St Leonards | قيد التجنيد | |
| Research Site | Waitara | قيد التجنيد |
Brazil
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Research Site | Belo Horizonte | لم يبدأ التجنيد بعد | |
| Research Site | Brasília | لم يبدأ التجنيد بعد | |
| Research Site | Campinas | لم يبدأ التجنيد بعد | |
| Research Site | Campinas | لم يبدأ التجنيد بعد | |
| Research Site | Curitiba | مسحوب | |
| Research Site | Curitiba | لم يبدأ التجنيد بعد | |
| Research Site | Curitiba | لم يبدأ التجنيد بعد | |
| Research Site | Natal | لم يبدأ التجنيد بعد | |
| Research Site | Porto Alegre | لم يبدأ التجنيد بعد | |
| Research Site | Rio de Janeiro | لم يبدأ التجنيد بعد | |
| Research Site | São José dos Campos | لم يبدأ التجنيد بعد | |
| Research Site | São Paulo | لم يبدأ التجنيد بعد |
Bulgaria
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Research Site | Montana | لم يبدأ التجنيد بعد | |
| Research Site | Pleven | لم يبدأ التجنيد بعد | |
| Research Site | Plovdiv | قيد التجنيد | |
| Research Site | Sofia | قيد التجنيد | |
| Research Site | Sofia | قيد التجنيد | |
| Research Site | Sofia | قيد التجنيد | |
| Research Site | Varna | لم يبدأ التجنيد بعد | |
| Research Site | Yambol | قيد التجنيد |
Canada
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Research Site | Brampton | Ontario | قيد التجنيد |
| Research Site | Calgary | Alberta | قيد التجنيد |
| Research Site | Guelph | Ontario | قيد التجنيد |
| Research Site | Hamilton | Ontario | قيد التجنيد |
| Research Site | Mississauga | Ontario | قيد التجنيد |
| Research Site | Moncton | New Brunswick | قيد التجنيد |
| Research Site | Montreal | Quebec | قيد التجنيد |
| Research Site | New Westminster | British Columbia | قيد التجنيد |
| Research Site | North York | Ontario | قيد التجنيد |
| Research Site | Québec | Quebec | قيد التجنيد |
| Research Site | Québec | Quebec | قيد التجنيد |
| Research Site | Saint-Charles-Borromée | Quebec | قيد التجنيد |
| Research Site | Scarborough Village | Ontario | قيد التجنيد |
| Research Site | Sherbrooke | Quebec | قيد التجنيد |
| Research Site | Stoney Creek | Ontario | قيد التجنيد |
| Research Site | Stouffville | Ontario | قيد التجنيد |
| Research Site | Surrey | British Columbia | مسحوب |
يُدرَج 170 موقعاً إضافياً في سجل السجل.
مستندات الدراسة
لا تُرتبط أي مستندات في سجل السجل هذا.
التغيّرات عبر الزمن
- 30 أكتوبر 2026
أُضيف موقع
8 sites added (220 total)
212220